Osimertinib plus early brain radiation versus osimertinib alone
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed metastatic non-small cell lung cancer that can’t be cured with surgery or focused radiation to the chest area.
- Your lung tumor tests positive for a specific EGFR mutation known to respond to osimertinib (like exon 19 deletion or L858R).
- Your brain MRI shows brain metastases, and you have fewer than 20 brain spots at the study start; symptoms should be mild or none.
- You must be able to take osimertinib at the time the study starts, and your doctor must think you are eligible for SRS radiation.
- You have good enough overall health for study participation (ECOG score 0–2) and are expected to live at least 6 months.
- You have not previously had osimertinib, immune checkpoint cancer therapy, or any prior SRS/whole-brain radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a precise, high-dose type of radiation (called SBRT or SRS) to the targeted therapy pill osimertinib can better control lung cancer that has an EGFR mutation. If you have had a good response to osimertinib but still have a few remaining tumors, this combination may help improve outcomes.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.